Instil Bio, Inc. carries a market capitalization of 55.82M, placing it among publicly traded companies globally. Its enterprise value stands at 65.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 55.82M |
| Enterprise Value | 65.92M |
Instil Bio, Inc. currently has 6.78M shares outstanding.
| Shares Outstanding | 6.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.08 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | -1.64 |
| P/OCF Ratio | -1.64 |
Instil Bio, Inc. maintains a current ratio of 39.87, meaning it holds 39.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.95, indicating elevated leverage, while an interest coverage ratio of -8.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 39.87 |
| Quick Ratio | 15.79 |
| Debt / Equity | 76.95 |
| Debt / EBITDA | -1.96 |
| Interest Coverage | -8.20 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.64 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Instil Bio, Inc.'s stock has declined approximately -72.47492% over the past 52 weeks. The 50-day moving average sits at 8.20, while the 200-day moving average is 12.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -72.47492% |
| 50-Day Moving Average | 8.20 |
| 200-Day Moving Average | 12.85 |
| Average Volume (20 Days) | N/A |
EBITDA reached -43.45M, while operating income came in at -43.50M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -43.50M |
| Pretax Income | -47.38M |
| Net Income | -47.38M |
| EBITDA | -43.45M |
| EBIT | -43.50M |
| Earnings Per Share (EPS) | -7.06 |
Instil Bio, Inc. holds 74.57M in cash and equivalents against 85.19M in total debt, resulting in a net debt position of 79.98M. Total book value stands at -730.69M, with working capital of 183.58M providing operational flexibility.
| Cash & Cash Equivalents | 74.57M |
| Total Debt | 85.19M |
| Net Debt | 79.98M |
| Equity (Book Value) | -730.69M |
| Book Value Per Share | -108.86 |
| Working Capital | 183.58M |
Instil Bio, Inc. produced -33.76M in operating cash flow over the past twelve months.
| Operating Cash Flow | -33.76M |
| Capital Expenditures | N/A |
| Free Cash Flow | -33.76M |
| FCF Per Share | -5.03 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.76 |
| FCF Yield | -61.04 |
Instil Bio, Inc.'s most recent stock split took place on December 8, 2023 with a 20:1 split ratio.
| Last Split Date | 12/8/2023 |
| Split Ratio | 20:1 |
Instil Bio, Inc. posts an Altman Z-Score of -4.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.35 |